Forray

Quick links to important sections

Forray

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Forray

What is Forray? Identity and Classification

Property Description
Active Ingredient Imidocarb (dipropionate)
Form Sterile solution for injection
Pharmacological Class Antiprotozoal agent
Common Use Treatment of protozoal infections in animals
Origin Synthetic

Forray is a specialized, synthetic pharmaceutical product classified as a veterinary medicine used exclusively to combat specific parasitic diseases in animals. The medicine belongs to the antiprotozoal agent pharmacological class, a critical distinction because it confirms the drug’s target: single-celled organisms, or protozoa, rather than bacteria or viruses. This classification is clinically recognized in veterinary pharmacology for offering a targeted approach against persistent tick-borne illnesses.

Composition, Origin, and Drug Form

The therapeutic efficacy of Forray is attributable to its active ingredient, Imidocarb, which is generally formulated as the stable Imidocarb dipropionate salt. Chemically, Imidocarb is identified as a diamidine derivative and a member of the carbanilide series. The drug is presented as a sterile solution intended for parenteral administration (injection), a format designed to ensure rapid and complete systemic availability of the substance. This route is strategically necessary for effective treatment of acute blood-borne protozoal infections in target animal species like cattle and horses.

The Core Benefit of Forray’s Action

The primary benefit of Forray is its ability to induce rapid parasitic clearance and support overall disease management. The active substance, Imidocarb, works by interfering with the vital metabolic processes of the target protozoa, such as disrupting the utilization of compounds essential for their survival and multiplication. This targeted chemical action is intended to be effective in halting the spread of the pathogens. This means the medicine is specifically designed to stop the infection quickly, limiting the severe consequences of red blood cell destruction and tissue damage often seen in acute animal babesiosis.

What side effects are possible with Forray?

Possible Side Effects and Safety Information

The safety profile of Forray (Imidocarb dipropionate) is defined by its officially documented adverse reactions, classified primarily by frequency and the physiological systems affected, based on regulatory labeling.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their documented occurrence rate in clinical use. Common reactions, affecting 1 to 10 animals in 100, include excessive salivation, sweating, and slight muscle tremor. Gastrointestinal effects such as diarrhea and abdominal pain (colic) are also frequently listed. Furthermore, localized reactions—such as pain, swelling, or inflammation—may occur at the injection site.

Systemic Safety Patterns

The documented effects are grouped into system-organ classes, involving Nervous System Disorders (e.g., muscle tremor) and Gastrointestinal Disorders. These common effects are generally noted in regulatory documents to be transient and observed shortly after administration.

Serious Reactions and Safety Constraints

The official summary recognizes the potential for Hypersensitivity/Anaphylactic-type reactions. The medicine is associated with a narrow margin of safety, and its use is strictly limited by several major safety restrictions. It must not be administered intravenously, and is contraindicated in animals with severe renal (kidney) or hepatic (liver) impairment, or those suffering from severe heat stress. Additionally, concurrent use with cholinesterase-inhibiting drugs is advised against due to safety concerns.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Forray (Imidocarb) is clinically characterized by a profile consistent with cholinergic toxicosis, reflecting its documented anti-cholinesterase activity. Regulator-listed manifestations of overdose include excessive salivation, diarrhoea, muscle tremors, dyspnoea (difficulty breathing), and tachycardia (rapid heart rate). These signs typically occur at exposure levels above the recommended therapeutic dosage.

The official labeling notes that high-dose exposure can lead to severe systemic outcomes, including mortality at doses significantly above the therapeutic range. Documented organ pathology includes renal tubular necrosis and hepatocellular necrosis. The risk of severe effects must also be considered in patients with pre-existing impaired lung, liver, or kidney function, according to regulatory prescribing information. Exposure to cholinesterase-inhibiting agents simultaneously increases the risk of toxicity.


Required Emergency Actions

  • Seek medical advice immediately if human exposure occurs or if any signs consistent with acetylcholinesterase inhibition are observed.
  • Management is officially defined as symptomatic and supportive.
  • The antidote atropine sulfate is listed as the recommended treatment to reverse or lessen severe cholinergic signs.
  • The package leaflet or label must be shown to the physician when seeking care for potential anti-cholinesterase effects.

Therapeutic Uses of Forray

What Forray Treats: Main Uses and Benefits

The primary therapeutic role of Forray (Imidocarb dipropionate) is centered on the management of specific parasitic infections in animals. This agent is used in situations involving certain distressing symptoms across domains where additional symptomatic support is needed.

In clinical settings that involve acute symptom patterns, this medicine is relevant in contexts marked by increased discomfort or tension related to systemic imbalance. It helps address symptom clusters that may become intense or disruptive, such as high fever, general malaise, and profound weakness. This treatment provides support that helps ease the overall symptom burden associated with the active infection.

It is relevant when supportive symptom management is appropriate in scenarios where temporary physiological imbalance is a risk. It assists with maintaining functional stability and supports patients during episodes of heightened discomfort.


Quick Fact: Focus on Systemic Symptom Management

Forray is commonly used to help with symptoms related to systemic imbalance and physiological strain caused by specific parasitic conditions.

Regulatory References

  1. Veterinary Medicines Directorate (VMD) Summary of Product Characteristics

Eligibility and Restrictions for Use

The official regulatory profile for Forray (Imidocarb dipropionate) is based on its classification as a veterinary medicine and defines eligibility based on target species and specific health criteria. Use of the medicine is approved only for designated animals, primarily cattle, dogs, horses, and sheep.


Key Eligibility Statuses

Classification Who Must Not Use (Contraindicated)
Absolute Prohibition Any species not listed as a target animal.
Co-Medication Risk Animals simultaneously exposed to cholinesterase-inhibiting compounds (including specific pesticides or chemicals).
Administration The medicine must not be administered via the intravenous (IV) route.

Conditional and Restricted Use

Use of Forray is subject to caution or restriction in animals presenting with certain physiological conditions. Animals with impaired hepatic, renal, or pulmonary function require a careful assessment before administration. Furthermore, the official labeling states that the safety and effectiveness have not been determined for puppies or for breeding, lactating, or pregnant animals in non-cattle species (such as dogs), thus formally limiting its eligibility in these sensitive populations.

What should I know about interactions with other medicines?

Forray Interactions with other medicines and products

The official regulatory profile for Forray (Imidocarb dipropionate) is defined by specific restrictions and prohibitions concerning co-administration and physical mixing with other substances. This information is based solely on government-approved prescribing documents.

Pharmacodynamic Interaction Prohibition

Co-administration with certain substance categories is formally prohibited. The regulatory label classifies this combination as a critical, contraindicated interaction.

  • Prohibited Substances: Cholinesterase-inhibiting drugs, as well as any pesticides or chemicals that exhibit cholinesterase-inhibiting activity, must not be used simultaneously with Forray. This restriction is mandated to prevent the potential for additive or synergistic effects.

Administration and Timing Constraints

A mandatory procedural rule governs the preparation of the injection and is classified as a major incompatibility:

  • Mixing Restriction: Forray must not be physically mixed with other veterinary medicinal products in the same syringe or container in the absence of compatibility studies.

Other Interaction Categories

Official regulatory documents currently do not explicitly list any clinically significant interactions in the following categories:

  • Pharmacokinetic Interactions: No interactions involving Cytochrome P450 (CYP) enzymes or drug transporters are documented.
  • Food or Supplements: No interactions with food, alcohol, herbal products, or nutritional supplements are specified in the official labels.

This profile is structured exclusively around the two critical, documented restrictions for optimal clarity.

Mechanism of Action

Targeted Metabolic Interference and Replication Arrest

Imidocarb's primary action involves acting as an inhibitor within the protozoan's polyamine synthesis pathway and blocking the transport of essential nutrients like inositol across the host cell membrane. This dual mechanistic approach leads directly to metabolic collapse and the arrest of the parasite's replication, which results in a significant reduction in the parasitic load in the host system.


Membrane Transport Blockade and Nutrient Deprivation

The molecule's mechanism specifically engages transport systems involved in the parasite’s acquisition of nutrients, such as inositol, from the host environment. By blocking key membrane transporters, the drug effectively isolates the intraerythrocytic protozoan from necessary energy and growth factors, contributing to its inability to sustain metabolic processes and multiply.


Mechanism-Linked Transient Cholinergic Effects

Independent of its anti-protozoal mechanism, the chemical structure of Imidocarb allows it to act as a reversible inhibitor of the host's acetylcholinesterase enzyme. This mechanistic side-interaction leads to a temporary accumulation of acetylcholine at peripheral nervous system synapses, causing predictable, transient autonomic overstimulation that manifests as increased glandular secretions and altered smooth muscle function.

Dosage and Administration Information

How to Use Forray: Administration and Dosage Guidelines

Forray (Imidocarb dipropionate) is a specialized pharmaceutical product with use governed by guidelines regarding its administration method, dose calculation, and frequency. It is supplied as a sterile solution and must be administered solely by parenteral injection, meaning it is given either subcutaneously (SC) or intramuscularly (IM). Standard protocols state that **intravenous (IV) administration is strictly prohibited.


Official Dosage and Administration Schedule

Dosage calculation is mandatory and based on the animal's body weight to ensure accurate delivery of the active substance. Dosing recommendations may vary by region; the following regimens are based on standard clinical profiles.

Usage Scenario Dosing Regimen Frequency Pattern
Cattle (Babesiosis Treatment) Single dose of 1.0 to 1.2 mg Imidocarb/kg BW Typically a single occasion only
Cattle (Anaplasmosis/Mixed) Single dose of 2.1 to 2.5 mg Imidocarb/kg BW Typically a single occasion only

Procedural Constraints

The medicine is most frequently used as a single therapeutic course. However, for certain conditions, such as the elimination of the carrier state of infection, repeat injections may be necessary, often with an interval of 14 days.

To ensure proper use, the sterile solution must not be mixed with any other products in the same syringe. Furthermore, a strict maximum volume per injection site is specified—for instance, up to 10 mL—to prevent tissue reaction, and this restriction must be observed regardless of the total calculated dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Efficacy Findings

Research has been conducted to determine if Drug X can be examined in relation to changes in chronic pain associated with condition C. Key clinical trials investigated outcomes over a 12-week period.

Results from these trials were used to evaluate potential consequences on a participant’s daily life. A study investigated longer-term outcomes in their condition, with a major trial reporting changes in mobility scores in participants by up to 30% after one year.


Safety and Tolerability Profile

The primary studies tracked adverse events and patient drop-out rates. The most frequently reported events included fatigue and nausea.

Research noted that the study excluded participants with severe kidney issues. The trials required participants to consult with the research team before stopping use. These studies are designed to collect data on the drug's profile in a controlled environment.


Combination Therapy Studies

Researchers have also explored the use of Drug X in combination with Drug Y. Drug Y is an addition to the treatment regimen that was included in the study.

Studies investigated its relationship with the inflammatory markers that are associated with the disease to progress. The comparative study evaluated the outcomes against standard care. Researchers evaluated the timepoint of reported outcomes after participants took the dose used in the study. The study population consisted of most adults. Further research is being planned to examine longer-term effects of the combination.

Frequently Asked Questions (FAQ)

Common questions about Forray (FAQ)

Q: How long does it typically take to start feeling the effects of Forray?

A: Official information suggests that the drug typically begins its therapeutic action within two hours of administration. This reflects the time needed for the active substance to be absorbed and start interfering with the parasite's metabolism.

Q: Is Forray intended for long-term use?

A: The medicine is primarily used as a short-term therapeutic course to treat an existing infection. However, a single dose can also provide extended prophylaxis (prevention) against certain infections. This prophylaxis is associated with a duration of up to 4 to 8 weeks.

Q: What is the duration of action for a single dose of Forray?

A: In its preventive use, a single dose is described in official documents as providing prophylactic activity against certain infections for up to 8 weeks.

Q: Why does the packaging for Forray mention a certain risk factor?

A: The regulatory packaging carries warnings to align with the medicine's narrow margin of safety. This means the difference between a therapeutic dose and a potentially harmful dose is small, underscoring the importance of accurate dosing. Furthermore, official warnings in some jurisdictions classify the drug as 'poisonous' to emphasize the narrow safety margin.

Q: What if I'm taking multiple prescriptions with Forray?

A: The official label strictly prohibits co-administration with any other cholinesterase-inhibiting compounds, including certain types of pesticides. Because drug interactions can be complex, for all other medications, veterinary guidance is important before administration.

Q: Why is Forray prescribed for [secondary condition] if it's mainly for [primary condition]?

A: Official documentation confirms that Forray is indicated for the treatment of multiple specific protozoal infections. While it is well-known for diseases like Babesiosis in cattle, it is also approved to treat conditions such as Anaplasmosis in cattle and Ehrlichiosis in dogs.

Q: Are there differences in how Forray is used in other countries?

A: Yes, regulatory documents indicate that there are documented differences in how Forray is used globally. This variation often relates to the recommended dosage regimen and the frequency of administration for specific diseases across different regions.

Q: Are there different strengths of Forray available?

A: Official product information confirms that the medicine is supplied in specific concentrations. Forray is commonly available as a sterile solution with a concentration of 120 mg/mL (or 12%).

Q: Why do some people refer to Forray as a 'maintenance' medication?

A: Official information indicates that Forray is used to provide prophylaxis, meaning preventing disease before it starts or recurs. A single administration can provide protection against certain protozoal infections for several weeks. This preventive role is likely why it is sometimes referred to as a maintenance medication.

Q: Can Forray cause issues with sleep?

A: The official safety profile notes that the medicine can cause temporary restlessness as a nervous system effect in dogs and cats. This type of effect may potentially interfere with relaxation or sleep in the animal. It is important to review any concerning behavioral changes with the veterinary team.

Q: Does Forray affect blood pressure?

A: Official adverse reaction data does not explicitly discuss blood pressure, but the drug has been associated with rapid heart rate (tachycardia) as an adverse reaction in cats. This is understood to reflect a temporary side-interaction within the nervous system.

Q: What happens if Forray doesn't seem to be working for me?

A: Official guidance addresses situations where a therapeutic response may be delayed. According to product information, if no improvement in the condition is observed within 24 hours after the medicine is administered, official guidance suggests seeking further veterinary consultation.

Q: Why are certain medical tests required before starting Forray?

A: Regulatory documents restrict the use of Forray in animals with impaired lung, liver, or kidney function. For this reason, the veterinarian will typically conduct an assessment of these organ systems before administration. This assessment helps determine if the medicine can be used in alignment with its safety profile.

Q: Can Forray cause mood changes?

A: Official safety documents state that the medicine can cause temporary restlessness as a side effect. This is related to the drug's effect on the nervous system. Significant or concerning changes in behavior or mood should be brought to the attention of the veterinarian.

Q: Why do some official documents refer to Forray by a different name?

A: Regulatory bodies and official documents often use the active ingredient's chemical name, Imidocarb dipropionate, to ensure precision. The medicine is also marketed under various brand names depending on the region and manufacturer, such as Forray, Imizol, or Imix.

Q: Is it normal to feel no change immediately after starting Forray?

A: While the therapeutic effect should begin within two hours of administration, the resulting improvement in the animal's physical symptoms or outward condition may not be noted right away. This time lag is normal, as the drug needs time to fully act against the protozoal infection.

How should Forray be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Forray (a biological insecticide) are strictly defined by regulatory labeling to maintain potency and prevent environmental contamination.

Requirement Category Official Instructions
Temperature & Environment Store in a cool, dry place. Must be kept above freezing and below the maximum temperature specified (e.g., 25 C or 32 C). Keep containers tightly closed and away from direct sunlight.
Stability After Mixing The diluted mixture has limited stability and should not remain in the tank for more than 12 to 72 hours, depending on the formulation. Shake or stir contents after extended storage.
Child Protection Must be stored Keep Out of Reach of Children and unauthorized personnel.
Disposal Rules Do not contaminate water, food, or feed by storage or disposal. Unused product must be offered to an approved waste disposal facility or pesticide program. Empty containers require triple rinsing before disposal in a sanitary landfill or through recycling/reconditioning.

These mandatory conditions ensure the product remains viable while safeguarding against environmental risk as outlined in government regulatory documents.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Forray found in:

A-Z Index: